Emerging Cardiorenal Protective Therapies in Lupus Nephritis - PubMed
3 days ago
- #cardiorenal protection
- #lupus nephritis
- #emerging therapies
- Emerging nephron-protective therapies, such as SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRAs, show potential for renal and cardiovascular benefits in lupus nephritis.
- These therapies work by reducing intraglomerular pressure, proteinuria, oxidative stress, and tubular inflammation, complementing standard immunomodulatory treatments.
- Early integration of cardio-renoprotective agents may delay progression to end-stage kidney disease and improve long-term outcomes in lupus nephritis patients.
- Future randomized trials in lupus nephritis cohorts are needed to define optimal timing, combinations, and safety alongside immunosuppression.